Scilex Holding Company reported its financial results for the third quarter of 2025, revealing a significant decline in revenue and a substantial increase in net losses compared to the same period in 2024. The company generated net revenue of $10.6 million for the three months ended September 30, 2025, down from $14.4 million in the prior year, primarily due to decreased sales of its flagship product, ZTlido. The total net loss for the quarter was $257.8 million, a stark increase from a loss of $4.4 million in the same quarter of 2024. For the nine months ended September 30, 2025, net revenue was $25.5 million, compared to $41.7 million in 2024, with a net loss of $327.9 million versus $66.3 million in the previous year.
The company's operational costs surged, with total net operating expenses reaching $197.1 million for the third quarter, compared to $34.4 million in the same quarter of 2024. This increase was largely attributed to a $140 million rise in selling, general, and administrative expenses, which included costs related to the reverse recapitalization with Denali Capital Acquisition Corp. Additionally, research and development expenses rose to $3.9 million, reflecting ongoing investments in product development, particularly for its late-stage candidates SEMDEXA, SP-103, and SP-104.
Scilex has also made strategic moves in its product portfolio, including the launch of ELYXYB in the U.S. in April 2023 and GLOPERBA in June 2024. The company is currently developing three product candidates, with SEMDEXA receiving fast track designation from the FDA. However, the company faces challenges, including a negative working capital of $342.5 million and an accumulated deficit of $888.7 million as of September 30, 2025. The company’s cash and cash equivalents stood at approximately $0.9 million, raising concerns about its ability to continue operations without additional funding.
Looking ahead, Scilex plans to pursue various funding strategies, including equity offerings and collaborations, to support its operations and product development. The company has expressed substantial doubt about its ability to continue as a going concern for the next year, emphasizing the need for significant additional capital to fund its commercialization efforts and ongoing research and development activities. The management's outlook indicates a focus on expanding its product offerings and addressing the financial challenges it currently faces.
About Scilex Holding Co
Scilex Holding Company develops and commercializes non-opioid pain management products, including FDA-approved topical and oral therapies for neuropathic pain, migraine, and gout. Its portfolio features innovative delivery systems and formulations targeting high unmet needs in acute and chronic pain markets. The company leverages proprietary technologies, strategic licensing, and a dedicated sales infrastructure to provide safer, effective alternatives to opioids for diverse patient populations.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov